PHIO Stock Summary and Trading Ideas (Phio Pharmaceuticals Corp. | NASDAQ:PHIO)

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Phio Pharmaceuticals Corp. trades on the NASDAQ stock market under the symbol PHIO.

As of September 15, 2026, PHIO stock price declined to $1.02 with 111,425 million shares trading.

PHIO has a beta of 0.29, meaning it tends to be less sensitive to market movements. PHIO has a correlation of 0.00 to the broad based SPY ETF.

PHIO has a market cap of $11.85 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PHIO traded as high as $29.07 and as low as $.81.

The top ETF exchange traded funds that PHIO belongs to (by Net Assets): VXF.

PHIO has underperformed the market in the last year with a price return of -53.2% while the SPY ETF gained +16.4%. PHIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.7% and -6.4%, respectively, while the SPY returned +2.4% and -1.3%, respectively.

PHIO support price is $.99 and resistance is $1.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHIO shares will trade within this expected range on the day.